Serum Institute of India (Covovax)
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeIngredient |
gptkb:NVX-CoV2373
|
| gptkbp:adjuvant |
gptkb:Matrix-M
|
| gptkbp:age |
adolescents
adults |
| gptkbp:basedOn |
Novavax NVX-CoV2373 technology
|
| gptkbp:brand |
gptkb:Covovax
|
| gptkbp:countryOfOrigin |
gptkb:India
|
| gptkbp:developedBy |
gptkb:Serum_Institute_of_India
|
| gptkbp:dosageSchedule |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Serum Institute of India (Covovax)
|
| gptkbp:manufacturer |
gptkb:Serum_Institute_of_India
|
| gptkbp:relatedTo |
gptkb:Novavax_COVID-19_vaccine
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:status |
approved in India
approved in several other countries |
| gptkbp:storage |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:WHO_EUL_status |
granted
|
| gptkbp:bfsParent |
gptkb:Novavax_COVID-19_vaccine
|
| gptkbp:bfsLayer |
5
|